Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy

Area of Science:

• Neurology
• Proteomics
• Vascular Biology

Background:

• Cerebral amyloid angiopathy (CAA) is a cerebrovascular disease characterized by amyloid-beta (Aβ) deposition in brain vessels.
• This deposition compromises vessel integrity, leading to lobar intracerebral hemorrhages, cognitive impairment, and transient neurological symptoms.

Purpose of the Study:

• To review the epidemiology, pathology, clinical, and radiological features of CAA.
• To explore recent proteomic findings and identify key molecules involved in CAA pathogenesis.
• To discuss future research directions for CAA therapeutics and biomarkers.

Main Methods:

• Review of existing literature on CAA.
• Analysis of recent advances in mass spectrometry and vascular isolation techniques.
• Identification and discussion of CAA-associated molecules identified through proteomic analyses.

Main Results:

• Proteomic analyses identified key CAA-associated molecules including apolipoprotein E, clusterin, SRPX1, TIMP3, and HTRA1.
• These molecules play critical roles in amyloid-beta cytotoxicity, fibril formation, and cerebral vessel wall remodeling.
• Understanding these molecular interactions is crucial for developing effective CAA therapeutics.

Conclusions:

• Elucidating the precise pathogenesis of CAA is essential for therapeutic development.
• Key identified molecules offer potential targets for novel CAA treatments.
• Further research into these molecular interactions may also yield biomarkers for early CAA diagnosis.